RESULTS: SNP did not lead to any reduction in psychotic symptoms or improvement in SWM performance compared to placebo. CONCLUSIONS: Although this study was negative, it is possible that the beneficial effects of SNP may occur in patients with a shorter history of illness, or with more acute exacerbation of symptoms.
This is complete ■■■■■■■■ that this study failed. I read the report from the first studies in Brazil and they sounded too good to be true. This is clearly a case of big pharma sweeping this one under the rug because it would basically change the way psychosis is treated. Also it would be an embarrassment to a lot of doctors that they overlooked this common medicine for so long. I’m calling bs on this one
Correct me if I’m wrong but isn’t the proof of concept study taking pass at Mass General and NYU? The results weren’t supposed to be in until 2017.
I saw this on the FDA web page.